相关实验视频

Updated: Jun 23, 2025

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

探索新型迪拉泽普衍生物作为hENT1抑制剂和潜在的共价分子工具

Majlen A Dilweg¹, Marina Gorostiola González¹, Martijn D de Ruiter¹

¹Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, PO Box 9502, Leiden, The Netherlands.

Purinergic signalling

|June 15, 2024

概括

研究人员开发了新的迪拉泽普衍生物,作为强大的人类平衡核酸转运体1 (hENT1) 抑制剂. 确定了高亲和度的化合物,为研究hENT1提供了新的工具.

科学领域:

药理学药理学是指药理学的学科.
药用化学医学化学
生物化学生物化学

背景情况:

人类平衡核酸转运体1 (hENT1) 调节核酸转运,影响血管扩张,神经传递和免疫防御.
像迪拉泽普这样的hENT1抑制剂用于心血管疾病,在其他疾病中也有潜力.
在各种生理和病理过程中,hENT1的腺素运输至关重要.

研究的目的:

设计,合成和评估作为hENT1抑制剂的新型迪拉泽普衍生物.
探索结构-活动关系以改善hENT1亲和力.
为了确定具有潜在的共价结合能力的高亲和度hENT1抑制剂.

主要方法:

基于ST7092.2.的39个迪拉泽普类型的合成.
[3H]NBTI的位移测定用于测量结合亲和力.
分子对接研究来分析抑制剂-载体相互作用.

主要成果:

在trimethoxy-benzoates的替代模式下降了hENT1亲和力.
潜在的共价化合物14b,14c和14d表现出高亲缘关系 (1.117.5 nM).
没有观察到对C439的共价结合的证据,可能是由于核友反应性降低.

结论:

新的迪拉泽普衍生物被确定为活性hENT1抑制剂.
开发了第一种具有电友核弹头的高亲和度迪拉泽普衍生物.
这些发现支持基于结构的hENT1抑制剂和药理工具的设计.

关键词:

协同抑制剂协同抑制剂迪拉泽普 (Dilazep) 是一种药物.人类平衡核酸转运体1 1 溶解物载体是溶解物中的载体.结构活动关系结构活动关系

更多相关视频

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...